indatuximab ravtansine + pomalidomide + dexamethasone

**indatuximab ravtansine + pomalidomide + dexamethasone** is an investigational **combination regimen** being explored for the treatment of relapsed/refractory multiple myeloma. - **Indatuximab ravtansine** is an antibody-drug conjugate (ADC) targeting **CD138 (syndecan-1)** on myeloma cells, combining a monoclonal antibody (indatuximab, BT-062) with the cytotoxic agent DM4 (ravtansine), designed to deliver targeted chemotherapy and induce cell death specifically in CD138-expressing cells. - **Pomalidomide** is a third-generation immunomodulatory agent (IMiD) that enhances T- and NK-cell mediated cytotoxicity, modulates the tumor microenvironment, and promotes degradation of transcription factors important for myeloma cell survival, such as IKZF3 and IRF4. - **Dexamethasone** is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive effects, commonly used as part of myeloma regimens to induce apoptosis and reduce inflammation. Clinical trials are underway to assess the efficacy and safety of this triple combination, building on the established synergistic activity of pomalidomide and dexamethasone, with promising preclinical anti-myeloma activity observed when indatuximab ravtansine is added to IMiD regimens.